Traitement de la dermatite atopique : Qu’en est-il du baricitinib ?

Details

Supervisors

Tennstedt, Dominique

Faculty

Faculté de pharmacie et des sciences biomédicales

Degree label

Master [120] en sciences pharmaceutiques, à finalité spécialisée

Abstract

enAtopic dermatitis (AD) is one of the most common inflammatory skin conditions in adults. Intense itching and skin pain can be debilitating and heavily alter the quality of life of patients. For a very long time, the treatment choices were limited and, for the advanced stages of the disease, the therapies were sometimes ineffective and/or heavy and accompanied by several adverse effects. Now, many agents targeting more specific disease pathways are available or under development. The pathogenesis of AD involves several cytokines that use Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Therefore, the studies are conducted to prove the efficacy and the safety of JAK inhibitors in this dermatological disease. Baricitinib is the first, among these inhibitors, to be approved by the European Medicines Agency. This dissertation begins with an introduction about atopic dermatitis disease and its pathophysiological mechanisms. Then, we review the pharmacodynamics and pharmacokinetics of baricitinib. Finally, we detail the main studies carried out to demonstrate the efficacy and safety of this drug in the field of atopic dermatitis.